Albertine Jolanda Oldehinkel

Albertine Jolanda Oldehinkel

Auto-generated profile, based on publicly available information

Albertine Jolanda Oldehinkel

Interdisciplinary Center Psychopathology and Emotion Regulation (ICPE), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2018 in Nature Genetics
Verified
Journal Article
Open access
PDF file
TPThe Million Veteran Program
The Million Veteran Program
EEEvangelos Evangelou
Evangelos Evangelou
HWHelen R. Warren
Helen R. Warren
DMDavid Mosen-Ansorena
David Mosen-Ansorena
BMBorbala Mifsud
Borbala Mifsud
MCMark Caulfield
Mark Caulfield
High blood pressure is a highly heritable and modifiable risk factor for cardiovascular disease. We report the largest genetic association study of blood pressure traits (systolic, diastolic and pulse pressure) to date in over 1 million people of European ancestry. We identify 535 novel blood pressure loci that not only offer new biological insights into blood pressure regulation but also highlight shared genetic architecture between blood pressure and lifestyle exposures. Our findings identify new biological pathways for blood pressure regulation with potential for improved cardiovascular disease prevention in the future.

9 December 2021 in Nature
Verified
Journal Article
Closed access
PDF file
SGSarah E. Graham
Sarah E. Graham
SCShoa L. Clarke
Shoa L. Clarke
KWKuan-Han H. Wu
Kuan-Han H. Wu
Stavroula KanoniStavroula Kanoni
Stavroula Kanoni
GZGreg J. M. Zajac
Greg J. M. Zajac
CWCristen J. Willer
Cristen J. Willer

31 May 2019 in Nature Genetics
Verified
Journal Article
Open access
PDF file
LSLifelines Cohort Study
Lifelines Cohort Study
MWMatthias Wuttke
Matthias Wuttke
VPV. A. Million Veteran Program
V. A. Million Veteran Program
YLYong Li
Yong Li
MLMan Li
Man Li
CPCristian Pattaro
Cristian Pattaro
Chronic kidney disease (CKD) is responsible for a public health burden with multi-systemic complications. Through trans-ancestry meta-analysis of genome-wide association studies of estimated glomerular filtration rate (eGFR) and independent replication (n = 1,046,070), we identified 264 associated loci (166 new). Of these, 147 were likely to be relevant for kidney function on the basis of associations with the alternative kidney function marker blood urea nitrogen (n = 416,178). Pathway and enrichment analyses, including mouse models with renal phenotypes, support the kidney as the main target organ. A genetic risk score for lower eGFR was associated with clinically diagnosed CKD in 452,264 independent individuals. Colocalization analyses of associations with eGFR among 783,978 European-ancestry individuals and gene expression across 46 human tissues, including tubulo-interstitial and glomerular kidney compartments, identified 17 genes differentially expressed in kidney. Fine-mapping highlighted missense driver variants in 11 genes and kidney-specific regulatory variants. These results provide a comprehensive priority list of molecular targets for translational research.

27 August 2018 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
JPJoëlle A. Pasman
Joëlle A. Pasman
KVKarin J. H. Verweij
Karin J. H. Verweij
ZGZachary Gerring
Zachary Gerring
SSSven Stringer
Sven Stringer
SSSandra Sanchez-Roige
Sandra Sanchez-Roige
JVJacqueline Vink
Jacqueline Vink

16 November 2020 in Nature Human Behaviour
Verified
Journal Article
Closed access
PDF file
DKDesana Kocevska
Desana Kocevska
TLThom S. Lysen
Thom S. Lysen
ADAafje Dotinga
Aafje Dotinga
MKM. Elisabeth Koopman-Verhoeff
M. Elisabeth Koopman-Verhoeff
MLMaartje P. C. M. Luijk
Maartje P. C. M. Luijk
HTHenning Tiemeier
Henning Tiemeier

12 September 2017 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
EWEleanor Wheeler
Eleanor Wheeler
ALAaron Leong
Aaron Leong
CLChing-Ti Liu
Ching-Ti Liu
MHMarie-France Hivert
Marie-France Hivert
RSRona Strawbridge
Rona Strawbridge
JMJames B. Meigs
James B. Meigs
Glycated hemoglobin (HbA1c) is used to diagnose type 2 diabetes (T2D) and assess glycemic control in patients with diabetes. Previous genome-wide association studies (GWAS) have identified 18 HbA1c-associated genetic variants. These variants proved to be classifiable by their likely biological action as erythrocytic (also associated with erythrocyte traits) or glycemic (associated with other glucose-related traits). In this study, we tested the hypotheses that, in a very large scale GWAS, we would identify more genetic variants associated with HbA1c and that HbA1c variants implicated in erythrocytic biology would affect the diagnostic accuracy of HbA1c. We therefore expanded the number of HbA1c-associated loci and tested the effect of genetic risk-scores comprised of erythrocytic or glycemic variants on incident diabetes prediction and on prevalent diabetes screening performance. Throughout this multiancestry study, we kept a focus on interancestry differences in HbA1c genetics performance that might influence race-ancestry differences in health outcomes. Using genome-wide association meta-analyses in up to 159,940 individuals from 82 cohorts of European, African, East Asian, and South Asian ancestry, we identified 60 common genetic variants associated with HbA1c. We classified variants as implicated in glycemic, erythrocytic, or unclassified biology and tested whether additive genetic scores of erythrocytic variants (GS-E) or glycemic variants (GS-G) were associated with higher T2D incidence in multiethnic longitudinal cohorts (N = 33,241). Nineteen glycemic and 22 erythrocytic variants were associated with HbA1c at genome-wide significance. GS-G was associated with higher T2D risk (incidence OR = 1.05, 95% CI 1.04–1.06, per HbA1c-raising allele, p = 3 × 10−29); whereas GS-E was not (OR = 1.00, 95% CI 0.99–1.01, p = 0.60). In Europeans and Asians, erythrocytic variants in aggregate had only modest effects on the diagnostic accuracy of HbA1c. Yet, in African Americans, the X-linked G6PD G202A variant (T-allele frequency 11%) was associated with an absolute decrease in HbA1c of 0.81%-units (95% CI 0.66–0.96) per allele in hemizygous men, and 0.68%-units (95% CI 0.38–0.97) in homozygous women. The G6PD variant may cause approximately 2% (N = 0.65 million, 95% CI 0.55–0.74) of African American adults with T2D to remain undiagnosed when screened with HbA1c. Limitations include the smaller sample sizes for non-European ancestries and the inability to classify approximately one-third of the variants. Further studies in large multiethnic cohorts with HbA1c, glycemic, and erythrocytic traits are required to better determine the biological action of the unclassified variants. As G6PD deficiency can be clinically silent until illness strikes, we recommend investigation of the possible benefits of screening for the G6PD genotype along with using HbA1c to diagnose T2D in populations of African ancestry or groups where G6PD deficiency is common. Screening with direct glucose measurements, or genetically-informed HbA1c diagnostic thresholds in people with G6PD deficiency, may be required to avoid missed or delayed diagnoses.